Genedrive PLC Notice of Results (5998T)
16 11월 2023 - 4:00PM
UK Regulatory
TIDMGDR
RNS Number : 5998T
Genedrive PLC
16 November 2023
genedrive plc
("genedrive" or the "Company")
Notice of Results
Investor Presentation
genedrive plc (LSE: GDR) , the point of care molecular
diagnostics company, announces it will release its preliminary
results for the year ended 30 June 2023 on Thursday, 30 November
2023.
The Company will provide a live presentation to accompany the
results, presented by CEO, James Cheek and CFO, Russ Shaw on
Thursday, 30 November 2023 at 10.00am.
The presentation will be hosted through the digital platform
Investor Meet Company. Investors can sign up to Investor Meet
Company for free and add to meet genedrive plc via the following
link:
https://www.investormeetcompany.com/genedrive-plc/register-investor
For further details please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a pharmacogenetic testing company developing
and commercialising a low cost, rapid, versatile, simple to use and
robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key
genetic information that will help them make the right choices over
the right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront of work on Point
of Care pharmacogenetics. Pharmacogenetics looks at how your
genetics impacts a medicines ability to work for you. Therefore by
using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the
Genedrive(R) MT-RNR1 ID Kit, which is a single-use disposable
cartridge which circumvents the requirement for cold chain
logistics by providing temperature stable reagent test kits for use
on their proprietary test platform. This test allows clinicians to
make a decision on antibiotic use within 26 minutes, ensuring vital
care is delivered with no negative impact on the patient
pathway.
The Company has a clear commercial strategy focused on
accelerating growth through maximising in-market sales, geographic
and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBABFTMTBBBRJ
(END) Dow Jones Newswires
November 16, 2023 02:00 ET (07:00 GMT)
Genedrive (LSE:GDR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Genedrive (LSE:GDR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024